Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns speaks with Proactive following his move into the leadership role late last year. Amplia is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers. #ProactiveInvestors #AmpliaTherapeutics #asx #cancer #fibrosis #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Amplia Therapeutics CEO outlines 2023 milestones
